摘要
目的探讨COX-2蛋白在不同临床病理特征非小细胞肺癌(NSCLC)组织中的表达情况及其与肿瘤微血管密度(MVD)间的关系。方法采用免疫组化法的链霉菌抗生物素过氧化酶(S-P)法检测85例NSCLC组织和20例正常肺组织中COX-2、CD34表达情况。结果NSCLC组织中COX-2阳性表达率56.5%,显著高于肺良性病变组织中的阳性表达率5.0%(P<0.05);在腺癌组织中阳性表达率(75.0%)显著高于鳞癌组织中阳性表达率(40.0%)(P<0.05);在高、中、低分化鳞癌组织中阳性表达率分别为18.8%、35.7%、66.7%;在高、低分化腺癌组织中阳性表达率分别为58.8%、87.0%,差异均有统计学意义(P<0.05);在淋巴结转移组的肺癌组织中阳性表达率(70.0%)显著高于无淋巴结转移组中的阳性表达率(37.1%)(P<0.05);COX-2阳性组MVD值(50.44±9.09)显著高于COX-2阴性组MVD值(34.60±7.24)(P<0.05);经直线相关分析,两者呈正相关(r=0.876,P<0.01)。结论COX-2表达与肺癌分化程度密切相关,揭示了COX-2可以作为判断病情和评价预后的指标。COX-2表达与MVD呈正相关,推测其可能具有促进肿瘤血管生成的作用。
Objective To study the expression of COX-2 in non-small cell lung cancer and discuss its potential correlation with tumor microvascular density. Methods The expressions of COX-2 and CD34 were detected in 85 cases with NSCLC tissues and 20 cases with normal lung tissues by immunohistochemical Streptavidin-Peroxidase （S-P） method. Results The positive rate of COX-2 in 85 cases with lung carcinoma was 56.5 % ,its positive rate in 20 cases with normal lung tissues was 5 %. It showed the expressional significant difference existed between the lung carcinoma group and the normal lung tissues groups（ P 〈 0. 05 ）. In squamous cancer and adenoearcinoma, the positive rates of COX-2 expressions were 40.0% and 75.0%, respectively. The difference between them was significant （ P 〈 O. 05 ）. In well, moderately and poorly-differentiated squamous cancer groups, the positive rates were 18.8 %, 35.7 % and 66.7 %, respectively. In well and poorly-differentiated adenocarcinoma groups, the positive rates were 58.8% and 87.0%. In the groups with and without lymph node metastases, the rates were 37.1% and 70.0% respectively. All the differences among pathological grades were significant （P 〈 0.05）. The MVD in the COX-2 positive-expression group is significantly higher than that in COX-2 negative-expression group（ P 〈 0.05）. There is the positive linear correlation existed between them. Conclusions COX-2 expression is associated closely with pathological grades, it may be identified as a definite diagnostic and evaluating prognostic markers in NSCLC. It may also promote blood vessels formation in lung cancer.
出处
《肿瘤基础与临床》
2006年第5期360-362,共3页
journal of basic and clinical oncology
基金
河南省自然科学基金资助项目(编号:004022300)
